http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 21:51:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html si-local-file:///var/storage/secattach/20260717/26785542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html Fri, 17 Jul 2026 21:51:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html si-local-file:///var/storage/secattach/20260717/26785542.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+BREITMEYER+JAMES+B/26785542.html Fri, 17 Jul 2026 21:51:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html si-local-file:///var/storage/secattach/20260717/26785539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html si-local-file:///var/storage/secattach/20260717/26785539.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Wheadon+David+E./26785539.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html si-local-file:///var/storage/secattach/20260717/26785540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html si-local-file:///var/storage/secattach/20260717/26785540.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+Watson+W.+Mark/26785540.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html si-local-file:///var/storage/secattach/20260717/26785541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html si-local-file:///var/storage/secattach/20260717/26785541.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16++Filed+by%3A+HERON+ELAINE+J/26785541.html Fri, 17 Jul 2026 21:50:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html si-local-file:///var/storage/secattach/20260717/26784438.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html Fri, 17 Jul 2026 16:10:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html si-local-file:///var/storage/secattach/20260717/26784438.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+16/26784438.html Fri, 17 Jul 2026 16:10:00 -0400 O.20329759 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Press+Releases/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html <p align="justify">SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Results from the Annual Meeting indicate that two proposals were approved and one proposal was rejected by Vaxart stockholders.</p> <p align="justify">Stockholders voted in favor of the following proposals in alignment with the Board of Directors’ recommendations:</p> <ul type="disc"><li style="text-align:justify;">Election of six director nominees to serve http://www.streetinsider.com/Globe+Newswire/Vaxart+Announces+Results+of+Annual+Meeting+of+Stockholders/26784328.html Fri, 17 Jul 2026 16:05:00 -0400 A.23795053 O.20329759 O.30693091 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html si-local-file:///var/storage/secattach/20260707/26738884.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html Tue, 07 Jul 2026 08:01:00 -0400 O.20329759 VXRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html si-local-file:///var/storage/secattach/20260707/26738884.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Vaxart%2C+Inc.++++++++++++++For%3A+Jul+06/26738884.html Tue, 07 Jul 2026 08:01:00 -0400 O.20329759 VXRT http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html <p>Vaxart, Inc. (OTCQX: VXRT) released topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating an oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator.</p> <p>The cohort included 201 participants who received Vaxart's oral pill vaccine and 199 who received an approved mRNA vaccine, both targeting the XBB strain of SARS-CoV-2. No vaccine-related serious adverse events or sustained Grade 3 or higher adverse events were reported in either arm of the trial.</p> <p>The most common adverse events among oral pill vaccine recipients were malaise/fatigue (20.9%), headache (18.9%), and anorexia (10.0%). In the mRNA http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html Mon, 06 Jul 2026 16:01:18 -0400 A.60012002 O.20329759 O.69857460 VXRT http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html <p>Vaxart, Inc. (OTCQX: VXRT) released topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating an oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator.</p> <p>The cohort included 201 participants who received Vaxart's oral pill vaccine and 199 who received an approved mRNA vaccine, both targeting the XBB strain of SARS-CoV-2. No vaccine-related serious adverse events or sustained Grade 3 or higher adverse events were reported in either arm of the trial.</p> <p>The most common adverse events among oral pill vaccine recipients were malaise/fatigue (20.9%), headache (18.9%), and anorexia (10.0%). In the mRNA http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html Mon, 06 Jul 2026 16:01:18 -0400 A.60012002 O.20329759 O.69857460 VXRT http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html <p>Vaxart, Inc. (OTCQX: VXRT) released topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating an oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator.</p> <p>The cohort included 201 participants who received Vaxart's oral pill vaccine and 199 who received an approved mRNA vaccine, both targeting the XBB strain of SARS-CoV-2. No vaccine-related serious adverse events or sustained Grade 3 or higher adverse events were reported in either arm of the trial.</p> <p>The most common adverse events among oral pill vaccine recipients were malaise/fatigue (20.9%), headache (18.9%), and anorexia (10.0%). In the mRNA http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html Mon, 06 Jul 2026 16:01:18 -0400 A.60012002 O.20329759 O.69857460 VXRT http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html <p>Vaxart, Inc. (OTCQX: VXRT) released topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating an oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator.</p> <p>The cohort included 201 participants who received Vaxart's oral pill vaccine and 199 who received an approved mRNA vaccine, both targeting the XBB strain of SARS-CoV-2. No vaccine-related serious adverse events or sustained Grade 3 or higher adverse events were reported in either arm of the trial.</p> <p>The most common adverse events among oral pill vaccine recipients were malaise/fatigue (20.9%), headache (18.9%), and anorexia (10.0%). In the mRNA http://www.streetinsider.com/FDA/Vaxart+reports+no+serious+adverse+events+in+oral+COVID+vaccine+trial/26735311.html Mon, 06 Jul 2026 16:01:18 -0400 A.60012002 O.20329759 O.69857460 VXRT http://www.streetinsider.com/Press+Releases/Vaxart+Reports+Topline+12-Month+Safety+Data+From+the+400-Participant+Sentinel+Safety+Cohort+of+the+Phase+2b+Clinical+Trial+of+Its+Oral+Pill+COVID-19+Vaccine/26735298.html <p align="center"><em>No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported</em></p> <p>SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced topline data from the approximately 400-participant sentinel safety cohort of its Phase 2b clinical trial evaluating the Company’s oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. Participants in this safety cohort received Vaxart’s oral pill vaccine (201 participants dosed) or an approved mRNA vaccine (199 participants dosed) targeting the XBB strain of SARS-CoV-2, the virus that causes COVID-19. No http://www.streetinsider.com/Press+Releases/Vaxart+Reports+Topline+12-Month+Safety+Data+From+the+400-Participant+Sentinel+Safety+Cohort+of+the+Phase+2b+Clinical+Trial+of+Its+Oral+Pill+COVID-19+Vaccine/26735298.html Mon, 06 Jul 2026 16:01:00 -0400 A.60012002 O.20329759 O.69857460 VXRT